Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRN Amarin	$11.60 -0.7%	$10.02	$7.08 ▼ $17.58	$240.20M	0.66	76,185 shs	50,780 shs
DRUG Bright Minds Biosciences	$26.00 -4.9%	$31.56	$0.93 ▼ $79.02	$183.14M	-5.32	824,988 shs	26,263 shs
FHTX Foghorn Therapeutics	$4.14 -4.2%	$3.94	$2.94 ▼ $10.25	$230.77M	3.13	141,610 shs	388,693 shs
SGTX Sigilon Therapeutics	$22.47	$22.02	$3.77 ▼ $28.00	$56.40M	4.12	62,902 shs	N/A

Free Today: Your Guide to Smarter Options Trades

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRN Amarin	-0.68%	+4.41%	+7.81%	+7.03%	-30.95%
DRUG Bright Minds Biosciences	-4.94%	-10.38%	-15.31%	-30.18%	+2,160.87%
FHTX Foghorn Therapeutics	-4.17%	0.00%	-1.43%	-14.64%	-26.47%
SGTX Sigilon Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMRN Amarin	0.204 of 5 stars	1.0	2.0	0.0	0.0	2.1	0.0	0.0
DRUG Bright Minds Biosciences	3.1021 of 5 stars	3.6	5.0	0.0	0.0	2.5	2.5	0.0
FHTX Foghorn Therapeutics	2.3787 of 5 stars	3.6	2.0	0.0	0.0	2.7	1.7	0.6
SGTX Sigilon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRN Amarin	2.00	Hold	$7.00	-39.66% Downside
DRUG Bright Minds Biosciences	3.25	Buy	$83.25	220.19% Upside
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	192.87% Upside
SGTX Sigilon Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SGTX, AMRN, FHTX, and DRUG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	DRUG Bright Minds Biosciences	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/13/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	DRUG Bright Minds Biosciences	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/7/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
4/30/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
4/30/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/23/2025	FHTX Foghorn Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/23/2025	FHTX Foghorn Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Mkt Outperform	$9.00

(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRN Amarin	$214.11M	1.12	N/A	N/A	$1.35 per share	8.59
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$5.86 per share	N/A
FHTX Foghorn Therapeutics	$23.50M	9.82	N/A	N/A	($1.83) per share	-2.26
SGTX Sigilon Therapeutics	$12.94M	4.36	N/A	N/A	$15.68 per share	1.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRN Amarin	-$59.11M	-$3.64	N/A	N/A	N/A	-16.33%	-7.22%	-4.96%	7/30/2025 (Estimated)
DRUG Bright Minds Biosciences	-$2.06M	-$0.36	N/A	N/A	N/A	N/A	-5.85%	-5.68%	8/13/2025 (Estimated)
FHTX Foghorn Therapeutics	-$98.43M	-$1.36	N/A	N/A	N/A	-357.53%	N/A	-30.98%	8/7/2025 (Estimated)
SGTX Sigilon Therapeutics	-$43.56M	-$12.23	N/A	N/A	N/A	-171.29%	-83.07%	-38.17%	N/A

Latest SGTX, AMRN, FHTX, and DRUG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q2 2025	DRUG Bright Minds Biosciences	-$0.39	-$0.29	+$0.10	-$0.29	N/A	N/A
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million
5/7/2025	Q1 2025	AMRN Amarin	-$0.06	-$0.04	+$0.02	-$0.04	$50.75 million	N/A
3/12/2025	Q4 2024	AMRN Amarin	-$1.20	-$2.40	-$1.20	-$0.12	$32.37 million	$62.31 million
3/6/2025	Q4 2024	FHTX Foghorn Therapeutics	-$0.43	-$0.30	+$0.13	-$0.30	$8.56 million	$2.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
SGTX Sigilon Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRN Amarin	N/A	3.23	2.11
DRUG Bright Minds Biosciences	N/A	126.01	11.31
FHTX Foghorn Therapeutics	N/A	4.77	4.77
SGTX Sigilon Therapeutics	N/A	1.78	1.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRN Amarin	22.25%
DRUG Bright Minds Biosciences	40.52%
FHTX Foghorn Therapeutics	61.55%
SGTX Sigilon Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AMRN Amarin	3.30%
DRUG Bright Minds Biosciences	42.66%
FHTX Foghorn Therapeutics	7.58%
SGTX Sigilon Therapeutics	6.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRN Amarin	360	20.71 million	402.62 million	Optionable
DRUG Bright Minds Biosciences	N/A	7.04 million	4.04 million	Not Optionable
FHTX Foghorn Therapeutics	120	55.74 million	50.57 million	Optionable
SGTX Sigilon Therapeutics	62	2.51 million	2.35 million	Not Optionable

SGTX, AMRN, FHTX, and DRUG Headlines

Recent News About These Companies

Regenxbio expands MPS I gene therapy trial after first look at data

August 29, 2024 | pharmaphorum.com

Lilly & Co Eli's Net Worth

May 1, 2024 | benzinga.com

MCRB Seres Therapeutics, Inc.

April 14, 2024 | seekingalpha.com

Beam Therapeutics Inc.

October 22, 2023 | wsj.com

Eli Lilly Concludes Acquisition Of Sigilon Therapeutics

August 14, 2023 | markets.businessinsider.com

Lilly Completes Acquisition of Sigilon Therapeutics

August 14, 2023 | finance.yahoo.com

SGTX - Sigilon Therapeutics, Inc.

August 1, 2023 | finance.yahoo.com

Inside Eli Lilly's Strategic Investment In Sigilon: An Opportunity Overlooked

July 31, 2023 | msn.com

SIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon ...

July 21, 2023 | businesswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WMC, SGTX, AJX, IMNM

July 18, 2023 | markets.businessinsider.com

Canaccord Genuity Maintains Sigilon Therapeutics (SGTX) Buy Recommendation

July 6, 2023 | msn.com

Sigilon Therapeutics (SGTX) Price Target Decreased by 6.27% to 48.28

July 6, 2023 | msn.com

5 big deal reports: Overstock snags Bed Bath & Beyond IP; Visa pays $1B for Pismo

July 3, 2023 | msn.com

Shares of Cambridge biotech Sigilon soar after company OKs Eli Lilly buyout

June 30, 2023 | wickedlocal.com

Lilly of the valley provides big bounce-back for Sigilon via T1D takeover

June 30, 2023 | bioworld.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Sigilon Therapeutics, Inc. Buyout

June 29, 2023 | benzinga.com

Eli Lilly to buy Sigilon Therapeutics on a massive premium

June 29, 2023 | invezz.com

Moderna Billionaire Set to Score 3,000% Gain on Tiny Biotech

June 29, 2023 | finance.yahoo.com

Eli Lilly and Company: Lilly to Acquire Sigilon Therapeutics

June 29, 2023 | finanznachrichten.de

Health Care Company Eli Lilly Announces Acquisition of Sigilon Therapeutics

June 29, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGTX, AMRN, FHTX, and DRUG Company Descriptions

Amarin NASDAQ:AMRN

$11.60 -0.08 (-0.68%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$11.64 +0.04 (+0.34%)

As of 05/30/2025 06:35 PM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Bright Minds Biosciences NASDAQ:DRUG

$26.00 -1.35 (-4.94%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$27.00 +1.00 (+3.85%)

As of 05/30/2025 07:52 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Foghorn Therapeutics NASDAQ:FHTX

$4.14 -0.18 (-4.17%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$4.08 -0.06 (-1.45%)

As of 05/30/2025 04:04 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Sigilon Therapeutics NASDAQ:SGTX

Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time